Understanding the Treatment Options Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics

Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics
Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics


Chemotherapy-Induced Nausea and Vomiting: A Common Side Effect of Cancer Treatment

Chemotherapy is a widely used treatment for various types of cancers. However, one of the most common and debilitating side effects of chemotherapy is nausea and vomiting. Chemotherapy can trigger nausea and vomiting due to the toxic effects of the anticancer drugs on the gastrointestinal tract. This side effect is known as chemotherapy-induced nausea and vomiting Cancer Chemotherapy Associated Nausea And Vomiting Therapeutics Around 70-80% of cancer patients receiving highly emetogenic chemotherapy experience CINV. Even patients receiving moderately emetogenic chemotherapy have a 30-60% risk of developing CINV. Left untreated, CINV can negatively impact a patient's quality of life and tolerance to chemotherapy. Therefore, it is crucial to manage CINV effectively using antiemetic medications.


Classification of Chemotherapy-Induced Nausea and Vomiting

CINV is classified based on the risk levels associated with specific chemotherapy regimens:

- Highly Emetogenic Chemotherapy (HEC): Chemotherapy drugs that cause vomiting in over 90% of patients without preventive treatment. Examples include cisplatin, carboplatin, doxorubicin, etc.

- Moderately Emetogenic Chemotherapy (MEC): Chemotherapy drugs with moderate emetogenic potential that cause vomiting in 30-90% of patients without preventive treatment. Examples are oxaliplatin, irinotecan, paclitaxel, cyclophosphamide, etc.

- Low Emetogenic Chemotherapy (LEC): Chemotherapy drugs with low emetogenic potential that cause vomiting in less than 30% of patients. Examples include fluorouracil, methotrexate, etc.

Antiemetic Medications for CINV Prevention and Treatment

Several classes of antiemetic medications are used to prevent and treat CINV based on the risk classification:

- 5-HT3 receptor antagonists: Ondansetron, granisetron, palonosetron, etc. block the serotonin receptor mainly responsible for CINV arising from chemotherapy. Given before and after chemotherapy.

- NK1 receptor antagonists: Aprepitant, fosaprepitant, netupitant-palonosetron, etc. work against substance P that mediates nausea and vomiting signals to the brain. Given before chemotherapy.

- Corticosteroids: Dexamethasone aids in reducing inflammation in the gut caused by chemotherapy. Given before and after chemotherapy.

- Dopamine receptor antagonists: Metoclopramide, prochlorperazine, etc. inhibit dopamine receptors involved in vomiting response. Used to treat breakthrough vomiting.

- Benzodiazepines: Lorazepam, alprazolam provide anxiolytic effects and additional antiemetic coverage when needed.

Guidelines for Antiemetic Prophylaxis

Treatment guidelines from NCCN, MASCC/ESMO, and ASCO recommend antiemetic combinations based on chemotherapy emetogenicity:

- HEC: Combination of a 5-HT3 receptor antagonist, NK1 receptor antagonist, and dexamethasone for 3 days.

- MEC: Combination of a 5-HT3 receptor antagonist and dexamethasone for 1-2 days.

- LEC: No routine prophylaxis needed but patients with high risk factors may benefit from a single dose of 5-HT3 antagonist.

Breakthrough CINV should be treated with dopamine antagonists, corticosteroids, or benzodiazepines. The guidelines also recommend switching or adding agents for refractory cases not responding to initial antiemetic prophylaxis.

Newer Antiemetic Options

Several newer antiemetic medications have been developed in recent years to address unmet needs in CINV management:

- Netupitant-palonosetron (Akynzeo): A fixed-dose combination of an NK1 receptor antagonist and the 5-HT3 receptor antagonist palonosetron for HEC-associated CINV.

- Rolapitant (Varubi): Second generation oral NK1 receptor antagonist offering longer blockade duration compared to aprepitant.

- Fosaprepitant (Emend-IV): Water-soluble prodrug of aprepitant given as a single intravenous infusion for improved convenience over oral aprepitant.

- Olanzapine (Zyprexa): Atypical antipsychotic found to have antiemetic properties against both acute and delayed nausea when added to standard antiemetics.

- Cannabinoids (Dronabinol, Nabilone): May offer additional benefit in refractory CINV cases unresponsive to standard treatments.

various classes of antiemetic medications continue to improve management of CINV as a debilitating chemotherapy side effect. Treatment guidelines recommend optimizing antiemetic prophylaxis based on chemotherapy emetogenicity. Newer agents are further enhancing control of nausea and vomiting for cancer patients undergoing chemotherapy. With the availability of well-studied and effective antiemetic options, CINV need no longer be the dose-limiting factor for administering chemotherapy. 

Get more insights, On Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics

 

Comments

Post a Comment

Popular posts from this blog

In-Vehicle Payment Services: The Evolution of Vehicle Payment Services

Image
In-Vehicle Payment Services The Rise of In-Vehicle Payment Services Over the past decade, contactless payments have seen a meteoric rise in popularity. With tap-and-go cards and mobile wallets, consumers enjoy the ease and convenience of making quick purchases without cash or even touching their payment terminal. This trend towards touchless transactions was already well underway when the Covid-19 pandemic accelerated its adoption out of health and safety concerns. As consumers have embraced contactless payments in their daily lives, the automotive industry has taken notice and begun exploring integrated payment solutions for vehicles. Embedded Payment Systems Major automakers have started equipping new In-Vehicle Payment Services with the capability to accept contactless payments right from the dashboard or center console. Systems like GM's Marketplace allow drivers to make purchases and pay for services without ever leaving the vehicle. Embedded payment terminals transmit a...
Read more

Guidewires: Revolutionizing Medical Procedures

Image
Guidewires In the world of modern medicine, innovative technologies are constantly emerging to enhance patient care and improve surgical procedures. One such groundbreaking advancement is the development and application of guidewires. These slender and flexible wires have revolutionized medical procedures, providing healthcare professionals with precise navigation and improved outcomes. Guidewires serve as essential tools in various medical specialties, including cardiology, radiology, and minimally invasive surgery. These thin wires are typically made of materials like stainless steel, nitinol (a nickel-titanium alloy), or polymer, which combine flexibility and strength to navigate through complex anatomical structures. In interventional cardiology, guidewires play a crucial role in the diagnosis and treatment of cardiovascular diseases. Cardiologists use guidewires to access blood vessels, guide catheters to the desired location, and navigate through intricate pathways of the hea...
Read more

The Quantum Advantage: How Quantum Sensors Are Redefining Sensing Applications

Image
Quantum sensors Quantum sensors are emerging as a game-changing technology, revolutionizing the field of sensing and measurement. By leveraging the principles of quantum mechanics, these sensors offer unparalleled precision, sensitivity, and accuracy, surpassing the capabilities of traditional sensors. The quantum advantage lies in their ability to exploit quantum phenomena, such as superposition and entanglement, to achieve remarkable performance in a wide range of sensing applications. One area where quantum sensors are making a significant impact is in navigation and positioning systems. Traditional GPS technology relies on signals from satellites, which can be affected by factors like signal degradation and interference. Quantum sensors, such as atomic clocks and quantum gyroscopes, provide more accurate and reliable positioning data, enabling precise navigation in challenging environments where GPS signals may be unreliable or inaccessible. This has far-reaching implications for...
Read more